Reduced insulin sensitivity is related to less endogenous dopamine at D2/3 receptors in the ventral striatum of healthy nonobese humans

International Journal of Neuropsychopharmacology

Volumn 18, Issue 7, 2015, Pages 1-10

  Caravaggio, Fernando ^a,b   Borlido, Carol ^a   Hahn, Margaret ^b,c   Feng, Zhe ^a   Fervaha, Gagan ^b   Gerretsen, Philip ^a,b,c   Nakajima, Shinichiro ^a,c   Plitman, Eric ^a,b   Chung, Jun Ku ^a,b   Iwata, Yusuke ^a,c   Wilson, Alan ^a,b,c   Remington, Gary ^a,b,c   Graff Guerrero, Ariel ^a,b,c  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b Institute of Medical Science   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

D2; Diabetes; Dopamine; Glucose; Insulin

Indexed keywords

DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; GLUCOSE; INSULIN; METIROSINE; NAXAGOLIDE C 11; TRACER; UNCLASSIFIED DRUG; CARBON; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; GLUCOSE BLOOD LEVEL; RACLOPRIDE;

ADULT; ARTICLE; DEPLETION; DOPAMINE DEPLETION; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; INSULIN SENSITIVITY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; VENTRAL STRIATUM; AGONISTS; ANALYSIS; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG EFFECTS; METABOLISM; POSITRON EMISSION TOMOGRAPHY; YOUNG ADULT;

ADULT; ALPHA-METHYLTYROSINE; BLOOD GLUCOSE; CARBON RADIOISOTOPES; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; FEMALE; HUMANS; INSULIN; MALE; POSITRON-EMISSION TOMOGRAPHY; RACLOPRIDE; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; VENTRAL STRIATUM; YOUNG ADULT;

EID: 84939190407     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1093/ijnp/pyv014     Document Type: Article

References (94)

1. Anthony K, Reed LJ, Dunn JT, Bingham E, Hopkins D, Marsden PK, Amiel SA (2006) Attenuation of insulin-evoked responses in brain networks controlling appetite and reward in insulin resistance: the cerebral basis for impaired control of food intake in metabolic syndrome? Diabetes 55:2986-2992.
2. Arneric SP, Chow SA, Bhatnagar RK, Webb RL, Fischer LJ, Long JP (1984) Evidence that central dopamine receptors modulate sympathetic neuronal activity to the adrenal medulla to alter glucoregulatory mechanisms. Neuropharmacology 23:137-147.
3. Bello NT, Hajnal A (2006) Alterations in blood glucose levels under hyperinsulinemia affect accumbens dopamine. Phys-iol Behav 88:138-145.
4. Bitar M, Koulu M, Rapoport SI, Linnoila M (1986) Diabetes-induced alteration in brain monoamine metabolism in rats. J Pharmacol Exp Ther 236:432-437.
5. Bradberry CW, Karasic DH, Deutch AY, Roth RH (1989) Region-ally-specifc alterations in mesotelencephalic dopamine synthesis in diabetic rats: association with precursor tyrosine. J Neural Transm Gen Sect 78:221-229.
6. Caravaggio F, Nakajima S, Borlido C, Remington G, Gerretsen P, Wilson A, Houle S, Menon M, Mamo D, Graff-Guerrero A (2014) Estimating endogenous dopamine levels at D2 and D3 Receptors in humans using the agonist radiotracer [C]-(+)-PHNO. Neuropsychopharmacology 30:125.
7. Caravaggio F, Raitsin S, Gerretsen P, Nakajima S, Wilson A, Graff-Guerrero A (2015) Ventral striatum binding of a dopamine d2/3 receptor agonist but not antagonist predicts normal body mass index. Biol Psychiatry 77:196-202.
8. Castonguay TW, Dubuc PU (1989) Insulin self-administration: effects on meal parameters. Appetite 12:202.
9. Chen CC, Yang JC (1991) Effects of short and long-lasting diabetes mellitus on mouse brain monoamines. Brain Res 552:175-179.
10. Chen PS, Yang YK, Yeh TL, Lee IH, Yao WJ, Chiu NT, Lu RB (2008) Correlation between body mass index and striatal dopamine transporter availability in healthy volunteers-a SPECT study. Neuroimage 40:275-279.
11. Chen S, Broqueres-You D, Yang G, Wang Z, Li Y, Wang N, Zhang X, Yang F, Tan Y (2013) Relationship between insulin resistance, dyslipidaemia and positive symptom in Chinese antipsy-chotic-naive frst-episode patients with schizophrenia. Psychiatry Res 210:825-829.
12. Crandall EA, Fernstrom JD (1983) Effect of experimental diabetes on the levels of aromatic and branched-chain amino acids in rat blood and brain. Diabetes 32:222-230.
13. Cumming P, Wong DF, Dannals RF, Gillings N, Hilton J, Scheffel U, Gjedde A (2002) The competition between endogenous dopamine and radioligands for specifc binding to dopamine receptors. Ann N Y Acad Sci 965:440-450.
14. Daws LC, Avison MJ, Robertson SD, Niswender KD, Galli A, Saun-ders C (2011) Insulin signaling and addiction. Neuropharma-cology 61:1123-1128.
15. Dunn JP, Kessler RM, Feurer ID, Volkow ND, Patterson BW, Ansari MS, Li R, Marks-Shulman P, Abumrad NN (2012) Relationship of dopamine type 2 receptor binding potential with fasting neuroendocrine hormones and insulin sensitivity in human obesity. Diabetes Care 35:1105-1111.
16. Fernandez-Egea E, Bernardo M, Parellada E, Justicia A, Garcia-Rizo C, Esmatjes E, Conget I, Kirkpatrick B (2008) Glucose abnormalities in the siblings of people with schizophrenia. Schizophr Res 103:110-113.
17. Figlewicz DP, Brot MD, McCall AL, Szot P (1996) Diabetes causes differential changes in CNS noradrenergic and dopaminergic neurons in the rat: a molecular study. Brain Res 736:54-60.
18. Figlewicz DP, Evans SB, Murphy J, Hoen M, Baskin DG (2003) Expression of receptors for insulin and leptin in the ventral tegmental area/substantia nigra (VTA/SN) of the rat. Brain Res 964:107-115.
19. Figlewicz DP, Bennett JL, Naleid AM, Davis C, Grimm JW (2006) Intraventricular insulin and leptin decrease sucrose self-administration in rats. Physiol Behav 89:611-616.
20. Galici R, Galli A, Jones DJ, Sanchez TA, Saunders C, Frazer A, Gould GG, Lin RZ, France CP (2003) Selective decreases in amphetamine self-administration and regulation of dopa-mine transporter function in diabetic rats. Neuroendocrinol-ogy 77:132-140.
21. Garcia BG, Wei Y, Moron JA, Lin RZ, Javitch JA, Galli A (2005) Akt is essential for insulin modulation of amphetamine-induced human dopamine transporter cell-surface redistribution. Mol Pharmacol 68:102-109.
22. Graff-Guerrero A, Willeit M, Ginovart N, Mamo D, Mizrahi R, Rusjan P, Vitcu I, Seeman P, Wilson AA, Kapur S (2008) Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans. Hum Brain Mapp 29:400-410.
23. Graff-Guerrero A, Redden L, Abi-Saab W, Katz DA, Houle S, Bar-soum P, Bhathena A, Palaparthy R, Saltarelli MD, Kapur S (2010) Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925. Int J Neu-ropsychopharmacol 13:273-287.
24. Grunberger G (2013) Novel therapies for the management of type 2 diabetes mellitus: part 1. pramlintide and bromocriptine-QR. J Diabetes 5:110-117.
25. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ (1997) Parametric imaging of ligand-receptor binding in PET using a simplifed reference region model. Neuroimage 6:279-287.
26. Guo J, Simmons WK, Herscovitch P, Martin A, Hall KD (2014) Striatal dopamine D2-like receptor correlation patterns with human obesity and opportunistic eating behavior. Mol Psychiatry 19:1078-1084.
27. Innis RB et al. (2007) Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27:1533-1539.
28. Johnson PM, Kenny PJ (2010) Dopamine D2 receptors in addiction-like reward dysfunction and compulsive eating in obese rats. Nat Neurosci 13:635-641.
29. Jouhaneau J, Le Magnen J (1980) Behavioral regulation of the blood glucose level in rats. Neurosci Biobehav Rev 1:53-63.
30. Kirkpatrick B, Fernandez-Egea E, Garcia-Rizo C, Bernardo M (2009) Differences in glucose tolerance between defcit and nondefcit schizophrenia. Schizophr Res 107:122-127.
31. Kirkpatrick B, Miller BJ, Garcia-Rizo C, Fernandez-Egea E, Bernardo M (2012) Is abnormal glucose tolerance in antipsychotic-naive patients with nonaffective psychosis confounded by poor health habits? Schizophr Bull 38:280-284.
32. Konner AC, Hess S, Tovar S, Mesaros A, Sanchez-Lasheras C, Evers N, Verhagen LA, Bronneke HS, Kleinridders A, Hampel B, Kloppenburg P, Bruning JC (2011) Role for insulin signaling in catecholaminergic neurons in control of energy homeostasis. Cell Metab 13:720-728.
33. Kono T, Takada M (1994) Dopamine depletion in nigrostriatal neurons in the genetically diabetic rat. Brain Res 634:155-158.
34. Kumar VSH, M BV, A NP, Aithal S, Baleed SR, Patil UN (2013) Bro-mocriptine, a dopamine (d2) receptor agonist, used alone and in combination with glipizide in sub-therapeutic doses to ameliorate hyperglycaemia. J Clin Diagn Res 7:1904-1907.
35. Kwok RP, Walls EK, Juorio AV (1985) The concentration of dopa-mine, 5-hydroxytryptamine, and some of their acid metabolites in the brain of genetically diabetic rats. Neurochem Res 10:611-616.
36. Kwok RP, Juorio AV (1986) Concentration of striatal tyramine and dopamine metabolism in diabetic rats and effect of insulin administration. Neuroendocrinology 43:590-596.
37. Labouebe G, Liu S, Dias C, Zou H, Wong JC, Karunakaran S, Clee SM, Phillips AG, Boutrel B, Borgland SL (2013) Insulin induces long-term depression of ventral tegmental area dopamine neurons via endocannabinoids. Nat Neurosci 16:300-308.
38. Lackovic Z, Salkovic M, Kuci Z, Relja M (1990) Effect of long-lasting diabetes mellitus on rat and human brain monoamines. J Neurochem 54:143-147.
39. Lammertsma AA, Hume SP (1996) Simplifed reference tissue model for PET receptor studies. Neuroimage 4:153-158.
40. Laruelle M, D'Souza CD, Baldwin RM, Abi-Dargham A, Kanes SJ, Fingado CL, Seibyl JP, Zoghbi SS, Bowers MB, Jatlow P, Char-ney DS, Innis RB (1997) Imaging D2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacol-ogy 17:162-174.
41. Lenoir M, Serre F, Cantin L, Ahmed SH (2007) Intense sweetness surpasses cocaine reward. PLoS One 2.
42. Levy JC, Matthews DR, Hermans MP (1998) Correct homeosta-sis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 21:2191-2192.
43. Lim DK, Lee KM, Ho IK (1994) Changes in the central dopaminer-gic systems in the streptozotocin-induced diabetic rats. Arch Pharm Res 17:398-404.
44. Lovestone S, Killick R, Di Forti M, Murray R (2007) Schizophrenia as a GSK-3 dysregulation disorder. Trends Neurosci 30:142-149.
45. Martinez D, Greene K, Broft A, Kumar D, Liu F, Narendran R, Slifstein M, Van Heertum R, Kleber HD (2009) Lower level of endogenous dopamine in patients with cocaine dependence: fndings from PET imaging of D(2)/D(3) receptors following acute dopamine depletion. Am J Psychiatry 166:1170-1177.
46. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419.
47. Mawlawi O, Martinez D, Slifstein M, Broft A, Chatterjee R, Hwang DR, Huang Y, Simpson N, Ngo K, Van Heertum R, Laruelle M (2001) Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab 21:1034-1057.
48. McQuade JA, Benoit SC, Xu M, Woods SC, Seeley RJ (2004) High-fat diet induced adiposity in mice with targeted disruption of the dopamine-3 receptor gene. Behav Brain Res 151:313-319.
49. Mebel DM, Wong JC, Dong YJ, Borgland SL (2012) Insulin in the ventral tegmental area reduces hedonic feeding and suppresses dopamine concentration via increased reuptake. Eur J Neurosci 36:2336-2346.
50. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP (2001) The continuing epidemics of obesity and diabetes in the United States. JAMA 286:1195-1200.
51. Morris JK, Bomhoff GL, Gorres BK, Davis VA, Kim J, Lee PP, Brooks WM, Gerhardt GA, Geiger PC, Stanford JA (2011) Insulin resistance impairs nigrostriatal dopamine function. Exp Neurol 231:171-180.
52. Murzi E, Contreras Q, Teneud L, Valecillos B, Parada MA, De Parada MP, Hernandez L (1996) Diabetes decreases limbic extracellular dopamine in rats. Neurosci Lett 202:141-144.
53. Nirenberg MJ, Chan J, Pohorille A, Vaughan RA, Uhl GR, Kuhar MJ, Pickel VM (1997) The dopamine transporter: comparative ultrastructure of dopaminergic axons in limbic and motor compartments of the nucleus accumbens. J Neurosci 17:6899-6907.
54. O'Dell LE, Natividad LA, Pipkin JA, Roman F, Torres I, Jurado J, Torres OV, Friedman TC, Tenayuca JM, Nazarian A (2014) Enhanced nicotine self-administration and suppressed dopaminergic systems in a rat model of diabetes. Addict Biol 19:1006-1019.
55. Owens WA, Sevak RJ, Galici R, Chang X, Javors MA, Galli A, France CP, Daws LC (2005) Defcits in dopamine clearance and locomotion in hypoinsulinemic rats unmask novel modulation of dopamine transporters by amphetamine. J Neurochem 94:1402-1410.
56. Owens WA, Williams JM, Saunders C, Avison MJ, Galli A, Daws LC (2012) Rescue of dopamine transporter function in hypoinsu-linemic rats by a D2 receptor-ERK-dependent mechanism. J Neurosci 32:2637-2647.
57. Pal GK, Pal P, Madanmohan (2002) Alteration of ingestive behaviours by nucleus accumbens in normal and streptozotocin-induced diabetic rats. Indian J Exp Biol 40:536-540.
58. Palmiter RD (2007) Is dopamine a physiologically relevant mediator of feeding behavior? Trends Neurosci 30:375-381.
59. Pan A, Lucas M, Sun Q, van Dam RM, Franco OH, Manson JE, Wil-lett WC, Ascherio A, Hu FB (2010) Bidirectional association between depression and type 2 diabetes mellitus in women. Arch Intern Med 170:1884-1891.
60. Potter GM, Moshirfar A, Castonguay TW (1999) Insulin affects dopamine overfow in the nucleus accumbens and the stria-tum. Physiol Behav 65:811-816.
61. Ricca V, Castellini G, Mannucci E, Monami M, Ravaldi C, Gorini Amedei S, Lo Sauro C, Rotella CM, Faravelli C (2009) Amphetamine derivatives and obesity. Appetite 52:405-409.
62. Saller CF (1984) Dopaminergic activity is reduced in diabetic rats. Neurosci Lett 49:301-306.
63. Saller CF, Kreamer LD (1991) Glucose concentrations in brain and blood: regulation by dopamine receptor subtypes. Brain Res 546:235-240.
64. Santiago JA, Potashkin JA System-based approaches to decode the molecular links in Parkinson's disease and diabetes. Neurobiol Dis. 2014 Apr 6. pii: S0969-9961(14)00080-1. doi: 10.1016/j.nbd.2014.03.019.
65. Schoffelmeer AN, Drukarch B, De Vries TJ, Hogenboom F, Schet-ters D, Pattij T (2011) Insulin modulates cocaine-sensitive monoamine transporter function and impulsive behavior. J Neurosci 31:1284-1291.
66. Seaquist ER (2014) Addressing the burden of diabetes. JAMA 311:2267-2268.
67. Searle G, Beaver JD, Comley RA, Bani M, Tziortzi A, Slifstein M, Mugnaini M, Griffante C, Wilson AA, Merlo-Pich E, Houle S, Gunn R, Rabiner EA, Laruelle M (2010) Imaging dopamine D3 receptors in the human brain with positron emission tomography, [11C]PHNO, and a selective D3 receptor antagonist. Biol Psychiatry 68:392-399.
68. Sevak RJ, Owens WA, Koek W, Galli A, Daws LC, France CP (2007) Evidence for D2 receptor mediation of amphetamine-induced normalization of locomotion and dopamine transporter function in hypoinsulinemic rats. J Neurochem 101:151-159.
69. Shotbolt P, Tziortzi AC, Searle GE, Colasanti A, van der Aart J, Abanades S, Plisson C, Miller SR, Huiban M, Beaver JD, Gunn RN, Laruelle M, Rabiner EA (2012) Within-subject comparison of [(11)C]-(+)-PHNO and [(11)C]raclopride sensitivity to acute amphetamine challenge in healthy humans. J Cereb Blood Flow Metab 32:127-136.
70. Siciliano CA, Calipari ES, Jones SR (2014) Amphetamine potency varies with dopamine uptake rate across striatal subregions. J Neurochem 2:12808.
71. Small DM, Jones-Gotman M, Dagher A (2003) Feeding-induced dopamine release in dorsal striatum correlates with meal pleasantness ratings in healthy human volunteers. Neuroim-age 19:1709-1715.
72. Studholme C, Hill DL, Hawkes DJ (1997) Automated three-dimensional registration of magnetic resonance and positron emission tomography brain images by multiresolution optimization of voxel similarity measures. Med Phys 24:25-35.
73. Thomsen G, Ziebell M, Jensen PS, da Cuhna-Bang S, Knudsen GM, Pinborg LH (2013) No correlation between body mass index and striatal dopamine transporter availability in healthy volunteers using SPECT and [123I]PE2I. Obesity 21:1803-1806.
74. Trulson ME, Himmel CD (1983) Decreased brain dopamine synthesis rate and increased [3H]spiroperidol binding in strepto-zotocin-diabetic rats. J Neurochem 40:1456-1459.
75. Tziortzi AC, Searle GE, Tzimopoulou S, Salinas C, Beaver JD, Jen-kinson M, Laruelle M, Rabiner EA, Gunn RN (2011) Imaging dopamine receptors in humans with [11C]-(+)-PHNO: dissection of D3 signal and anatomy. Neuroimage 54:264-277.
76. Ustione A, Piston DW (2012) Dopamine synthesis and D3 receptor activation in pancreatic beta-cells regulates insulin secretion and intracellular [Ca(2+)] oscillations. Mol Endocrinol 26:1928-1940.
77. van de Giessen E, Hesse S, Caan MW, Zientek F, Dickson JC, Tossici-Bolt L, Sera T, Asenbaum S, Guignard R, Akdemir UO, Knudsen GM, Nobili F, Pagani M, Vander Borght T, Van Laere K, Varrone A, Tatsch K, Booij J, Sabri O (2013) No association between striatal dopamine transporter binding and body mass index: a multi-center European study in healthy volunteers. Neuroimage 64:61-67.
78. van de Giessen E, Celik F, Schweitzer DH, van den Brink W, Booij J (2014) Dopamine D2/3 receptor availability and amphetamine-induced dopamine release in obesity. J Psychopharma-col 28:866-873.
79. Verhoeff NP, Kapur S, Hussey D, Lee M, Christensen B, Psych C, Papatheodorou G, Zipursky RB (2001) A simple method to measure baseline occupancy of neostriatal dopamine D2 receptors by dopamine in vivo in healthy subjects. Neuropsy-chopharmacology 25:213-223.
80. Volkow ND, Fowler JS, Wang GJ, Baler R, Telang F (2009) Imaging dopamine's role in drug abuse and addiction. Neuropharma-cology 1:3-8.
81. Volkow ND, Wang GJ, Tomasi D, Baler RD (2013a) The addictive dimensionality of obesity. Biol Psychiatry 73:811-818.
82. Volkow ND, Wang GJ, Tomasi D, Baler RD (2013b) Obesity and addiction: neurobiological overlaps. Obes Rev 14:2-18.
83. Wallace DL, Aarts E, Dang LC, Greer SM, Jagust WJ, D'Esposito M (2014) Dorsal striatal dopamine, food preference and health perception in humans. PLoS One 9.
84. Wallace TM, Levy JC, Matthews DR (2004) Use and abuse of HOMA modeling. Diabetes Care 27:1487-1495.
85. Wang GJ, Volkow ND, Logan J, Pappas NR, Wong CT, Zhu W, Netusil N, Fowler JS (2001) Brain dopamine and obesity. Lancet 357:354-357.
86. Wang GJ, Tomasi D, Convit A, Logan J, Wong CT, Shumay E, Fowler JS, Volkow ND (2014) BMI Modulates Calorie-Dependent Dopa-mine Changes in Accumbens from Glucose Intake. PLoS One 9.
87. Werther GA, Hogg A, Oldfeld BJ, McKinley MJ, Figdor R, Allen AM, Mendelsohn FA (1987) Localization and characterization of insulin receptors in rat brain and pituitary gland using in vitro autoradiography and computerized densitometry. Endocrinology 121:1562-1570.
88. West FH, Bond ED, Shurley JT, Meyers CD (1955) Insulin coma therapy in schizophrenia; a fourteen-year follow-up study. Am J Psychiatry 111:583-589.
89. Wilcox CE, Braskie MN, Kluth JT, Jagust WJ (2010) Overeating Behavior and Striatal Dopamine with 6-[F]-Fluoro-L-m-Tyros-ine PET. J Obes 909348:4.
90. Willette AA, Johnson SC, Birdsill AC, Sager MA, Christian B, Baker LD, Craft S, Oh J, Statz E, Hermann BP, Jonaitis EM, Koscik RL, La Rue A, Asthana S, Bendlin BB (2014) Insulin resistance predicts brain amyloid deposition in late middle-aged adults. Alzheimers Dement 17:02420-02420.
91. Williams JM, Owens WA, Turner GH, Saunders C, Dipace C, Blakely RD, France CP, Gore JC, Daws LC, Avison MJ, Galli A (2007) Hypoinsulinemia regulates amphetamine-induced reverse transport of dopamine. PLoS Biol 5.
92. Wilson AA, Garcia A, Jin L, Houle S (2000) Radiotracer synthesis from [(11)C]-iodomethane: a remarkably simple captive solvent method. Nucl Med Biol 27:529-532.
93. Wilson AA, McCormick P, Kapur S, Willeit M, Garcia A, Hussey D, Houle S, Seeman P, Ginovart N (2005) Radiosynthesis and evaluation of [11C]-(+)-4-propyl-3, 4, 4a, 5, 6, 10b-hexahydro-2H-naphtho[1, 2-b][1, 4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affnity state with positron emission tomography. J Med Chem 48:4153-4160.
94. Ziauddeen H, Farooqi IS, Fletcher PC (2012) Obesity and the brain: how convincing is the addiction model? Nat Rev Neu-rosci 13:279-286.